Eisai has announced a global agreement with the Broad Institute, a collaborative research facility that includes researchers from Harvard University and the Massachusetts Institute of Technology (MIT), to jointly discover and develop new therapeutic agents for the treatment of neglected tropical diseases (NTDs) and tuberculosis.
Under the agreement, Eisai and Broad will collaborate together on drug discovery initiatives toward novel treatments for NTDs and tuberculosis through optimization of compounds screened from Broad's chemical library. The first project will conduct drug discovery research aimed at the creation of a novel treatment for Chagas disease.
This first project for the treatment of Chagas disease has also been awarded a grant for partial funding by the Global Health Innovative Technology Fund (GHIT Fund), an international nonprofit organization aimed to advance the research and development of new health technologies from Japan to fight infectious diseases prevalent specifically in the developing world, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases (NTDs). Established as a public-private partnership between the Government of Japan, a consortium of pharmaceutical companies (including Eisai), and the Bill & Melinda Gates Foundation, the GHIT Fund facilitates and funds research and development of new health technologies.
|Location||Latin America and Caribbean, Venezuela, Uruguay, Trinidad and Tobago, Suriname, Saint Vincent and the Grenadines, Saint Lucia, Saint Kitts and Nevis, Peru, Paraguay, Panama, Nicaragua, Mexico, Jamaica, Honduras, Haiti, Guyana, Guatemala, Grenada, French Guiana, El Salvador, Ecuador, Dominican Republic, Dominica, Cuba, Costa Rica, Colombia, Chile, Brazil, Bolivia, Belize, Barbados, Bahamas, Argentina, Antigua and Barbuda|